title: A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis.
abstract: OBJECTIVE
  To compare the role of an aromatase inhibitor (letrozole) with a GnRH agonist (triptorelin) versus case control on the pregnancy rate and recurrence of symptoms and signs in patients with endometriosis.
  
  
  METHODS
  In a prospective randomized clinical trial, after treatment of 144 infertile women in their reproductive age by laparoscopy (whose endometriosis was confirmed by prior laparoscopy), they were divided into 3 groups: group 1 (47 cases) who received letrozole for 2 months, group 2 (40 patients) who were prescribed triptorelin for 2 months and group 3 who were 57 patients in the control group and did not receive any medication. We followed up each group at least for 12 months after their restoration of regular cycle.
  
  
  RESULTS
  Pregnancy rate was 23.4% in group 1, 27.5% in group 2, and 28.1% in group 3. The results did not show significant differences among the 3 groups. Recurrence rate of endometriosis was 6.4% in group 1, 5% group 2 and 5.3% in group 3, which was not statistically significantly different as well.
  
  
  CONCLUSIONS
  Pregnancy rate and endometriosis recurrence rate are comparable among the 3 groups.
authors.affiliation: Division of Infertility and Endoscopic Surgery, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. alborzis@sums.ac.ir
authors.forename: Saeed
authors.initials: S
authors.lastname: Alborzi
authors.forename: Bahareh
authors.initials: B
authors.lastname: Hamedi
authors.forename: Azizeh
authors.initials: A
authors.lastname: Omidvar
authors.forename: Sedigheh
authors.initials: S
authors.lastname: Dehbashi
authors.forename: Soroosh
authors.initials: S
authors.lastname: Alborzi
authors.forename: Mehrnoosh
authors.initials: M
authors.lastname: Alborzi
mesh_terms: D000328:Adult; D047072:Aromatase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004715:Endometriosis / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy* / Q000209:etiology; D010535:Laparoscopy; D000077289:Letrozole; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use*; D011184:Postoperative Period; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D055502:Secondary Prevention; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D017329:Triptorelin Pamoate / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D000077289:Letrozole